Physician profile
Ankur Arora
NPI 1760702922
$407.80
in general payments reported to CMS, 2019-2025
11 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.46 · 2023: $19.82 · 2024: $130 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $91.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.39 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $44.78 | 2024 | |
| Scpharmaceuticals INC. | $38.34 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.93 | 2024-2025 | Verquvo |
| Viatris Specialty LLC | $30.57 | 2025 | Yupelri |
| Boston Scientific Corporation | $25.16 | 2025 | Watchman Access System |
| Novo Nordisk INC | $19.82 | 2023 | Wegovy |
| Solventum Corporation | $18.99 | 2025 | V.A.C.Ulta |
| Alexion Pharmaceuticals, INC. | $16.23 | 2025 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $15.13 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.